In what Science magazine has dubbed “Novo Nordisk’s Canadian Mistake,” Ozempic is soon to come off patent in Canada, opening the door to cheaper generic copycats, after the drug giant reportedly ...

Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...

Biocon aims to introduce generic versions of the obesity drug Wegovy in India and Canada by late 2026 or early 2027, ...

A US doctor has explained the reality behind the 'Ozempic penis' side effect men have reported having after taking the GLP-1 drug ...

June 6 (Reuters) - Novo Nordisk's (NOVOb.CO) popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition that can lead to vision loss, the European ...

Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...

Novo Nordisk shares have come under pressure amid weight-loss drug competition, while UK health officials have launched a study into a side effect of the jabs.

Novo Nordisk’s annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 billion of sales worldwide.

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.

Novo Nordisk reveals three new weight loss drugs, aiming to offer diverse options for obesity and weight management. ... Ozempic maker announces not one, but three new weight-loss drugs ...

Ozempic, a type 2 diabetes treatment, presents investment opportunities via Novo Nordisk stock. Projected GLP-1 market growth to almost $160 billion by early the 2030s indicates long-term sector ...